Amgen spotlights rare disease pipeline after completing Horizon acquisition

Amgen touted its rare disease strategy on Thursday, highlighting the financial potential of both current blockbusters and other drugs in its pipeline.

The spotlight on rare diseases follows the completion of its $28 billion acquisition of Horizon Therapeutics in 2023. Amgen is now working to integrate Horizon and its pipeline…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks